Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly And Queensland Government Invest In First-ever Australian Biotech VC Fund

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Eli Lilly and the Queensland government have formed a $250 million venture capital fund to invest in Australia's biotech sector, Queensland Premier Anna Bligh announced May 20
Advertisement

Related Content

Australia Ramps Up Early Research Via Medical Research Commercialization Fund
CSL Invests $235 Million In Manufacturing Facility For Late-stage Development In Australia
CSL Invests $235 Million In Manufacturing Facility For Late-stage Development In Australia
Medicines Australia Negotiates Lower Off-patent Prices In Exchange For Level Prices For Innovative New Drugs In Newly Announced Federal Budget
Lilly CEO, In Shanghai, Predicts Better Patent Protection Will Unleash Scientific Innovation Across China
Lilly CEO, In Shanghai, Predicts Better Patent Protection Will Unleash Scientific Innovation Across China
What Financial Crisis? Australian Biotech Enters Golden Era (Part 2 of 2)
Advertisement
UsernamePublicRestriction

Register

SC074872

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel